Strattera (Atomoxetine).
The Non-Stimulant ADHD Option -- What It Does and Who It Helps.
Most ADHD medications are stimulants -- scheduled controlled substances that work immediately. Strattera (atomoxetine) is different. It is not a stimulant, not a controlled substance, and does not work the same day you take it. It works more like an antidepressant: you take it daily for weeks before seeing the full effect. For the right patient, this makes it a valuable option that other medications cannot replicate.
This article is for informational purposes only and does not replace a conversation with your prescriber. Medication decisions should always be made with a licensed provider who knows your full history.
What Is Strattera?
Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor (NRI). It works by blocking the reuptake of norepinephrine in the prefrontal cortex, which plays a central role in attention, impulse control, and working memory. Unlike SSRIs (which target serotonin) or stimulants (which flood dopamine and norepinephrine), atomoxetine specifically targets norepinephrine and builds effect gradually over time.
FDA-approved for:
- ADHD in adults
- ADHD in children age 6 and older
Who Is Strattera Best Suited For?
Strattera is particularly useful in situations where stimulants are not ideal:
- ADHD with significant anxiety. Stimulants can worsen anxiety, especially at higher doses. Atomoxetine does not cause the same activation and is often better tolerated in patients who have both ADHD and anxiety disorders.
- History of substance use disorder. Because Strattera is not a controlled substance and has no abuse potential, it is appropriate for patients with substance use histories where prescribing Schedule II medications raises legitimate concerns.
- Patients who prefer not to take a controlled substance. Some people -- for personal, occupational, or logistical reasons -- prefer to avoid controlled substance prescriptions.
- Patients whose sleep is severely disrupted by stimulants. Stimulants frequently worsen sleep; atomoxetine does not have this effect to the same degree.
- When stimulant supply or access is a barrier. Stimulant shortages have created real access problems in recent years. As a non-controlled medication, atomoxetine does not face the same prescription and supply constraints.
How Long Does It Take to Work?
This is the most important thing to understand about Strattera before starting: it does not work immediately. Most patients begin noticing some improvement around 2 to 4 weeks, with full effect at 6 to 12 weeks. This is similar to the timeline for antidepressants and is the biggest source of early discontinuation -- patients stop because they do not see immediate results, before the medication has had time to work.
Commit to the timeline. If you try Strattera for two weeks and feel nothing, that is expected -- not failure. The evaluation window is 6 to 8 weeks at an adequate dose, not 2 weeks.
Dosing
Atomoxetine is weight-based. Starting dose for adults is typically 40 mg daily, increased to 80 mg after 3 weeks, and optionally to 100 mg for additional effect. It can be taken once daily or split into morning and evening doses, which can improve tolerability. The dose can be increased gradually over weeks based on response.
Common Side Effects
- Nausea or upset stomach -- most common early on; taking with food helps significantly; usually improves within weeks
- Fatigue or sedation -- particularly early in treatment; often improves with time or by taking the dose in the evening
- Decreased appetite -- less pronounced than with stimulants but present
- Dry mouth
- Elevated heart rate and blood pressure -- modest; worth monitoring
- Sexual side effects -- reduced libido, delayed orgasm; similar to SNRI antidepressants
- Urinary hesitancy -- norepinephrine effects on the urinary tract
- Mood changes or irritability -- especially in the initial weeks
There is a black box warning on Strattera about increased suicidal ideation in children and adolescents -- the same class warning applied to all noradrenergic medications. Monitoring for mood changes is appropriate, particularly in younger patients and in the first months of treatment.
Strattera vs. Qelbree (Viloxazine)
Both are non-stimulant ADHD medications. Qelbree (viloxazine ER) is a newer option approved in 2021 with a somewhat different receptor profile. Both require weeks to build effect. See our Qelbree guide for a comparison.
See Also
Exploring non-stimulant ADHD options?
Alice Tran, PMHNP-BC, evaluates and treats ADHD in adults via telehealth and in person across Virginia. She will work with you to find the right medication approach for your full clinical picture.
Schedule a Consultation
Anh Tran (Alice), PMHNP, FNP-BC
Dual Board-Certified Family and Psychiatric Nurse Practitioner
Alice is a dual board-certified PMHNP and FNP licensed in Virginia. She provides compassionate, evidence-based psychiatric care via telehealth and in person. She is fluent in English and Vietnamese. Learn more →